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Lorenzo Maggi and Marina Mora*
Neuromuscular Diseases and Neuroimmunology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
Mutations in the DNAJB6 gene have been associated with the autosomal dominant
limb girdle muscular dystrophy type 1D (LGMD1D), a disorder characterized by
abnormal protein aggregates and rimmed vacuoles in muscle fibers. DNAJB6 is a
ubiquitously expressed Hsp40 co-chaperone characterized by a J domain that specifies
Hsp70 functions in the cellular environment. DNAJB6 is also a potent inhibitor of
expanded polyglutamine (polyQ) aggregation preventing aggregate toxicity in cells.
In DNAJB6-mutated patients this anti-aggregation property is significantly reduced,
albeit not completely lost. To elucidate the pathogenetic mechanisms underlying the
DNAJB6-related myopathy, animal models have been created showing that, indeed,
conditional muscular expression of a DNAJB6 mutant in the mouse causes a LGMD1D
myofibrillary muscle tissue phenotype. Both mutations and phenotypes reported until
recently were rather homogeneous, being exclusively missense mutations of a few amino
acids of the protein G/F domain, and with a phenotype characterized by adult-onset
slowly progressive muscular dystrophy predominantly affecting proximal muscles. Lately,
several novel mutations and new phenotypes of DNAJB6 have been described. These
mutations once more affect the G/F domain of DNAJB6 with missense changes and a
splice site mutation; and the phenotypes include childhood onset and distal involvement
of muscles, or childhood-onset LGMD1D with loss of ambulation in early adulthood and
respiratory involvement. Thus, the spectrum of DNAJB6-related phenotypes is widening.
Although our knowledge about the role of DNAJB6 in the pathogenesis of muscle
diseases has made great progression, several questions remain unsolved, including why
a ubiquitous protein affects only, or predominantly, skeletal muscle; why only the G/F
domain is involved; and what is the possible role of the DNAJB6a isoform. Clarification
of these issues will provide clues to implement possible therapeutic strategies for
DNAJB6-related myopathies.
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INTRODUCTION
The first description of what it was, at that time, defined as
“an unusual form of muscular dystrophy” dates back to 1969,
when Schneiderman et al. (1969) described a four generation
family affected by a late onset dominant muscular dystrophy
form, predominantly affecting proximal limb muscles. Neither
the genetic cause of this dystrophy nor the locus were at that point
clarified.
A step forward on the identification of the causative gene
for this form of limb girdle muscular dystrophy (LGMD),
now named LGMD1D, was taken by Speer et al. (1999)
who provided evidence of linkage to the 7q locus. In this
study Speer and colleagues gathered five families based on
the presence, in the affected members, of progressive proximal
lower limb muscle weakness with or without proximal upper
limb involvement, increased creatine kinase (CK) levels, absent
ankle deep tendon reflexes, and no features suggestive of any
other known myopathy, by muscle histology and electron
microscopy. Genome wide linkage excluded three of the five
families establishing evidence for linkage to 7q for the remaining
two, previously described by Schneiderman et al. (1969) and
Speer et al. (1995). Two recombination events in both families
allowed the authors to better define the region in an interval of 9
cM comprised between markers D7S2546 and D7S2423.
Few years passed by before new LGMD1D families were
reported in 2010 (Sandell et al., 2010). One year later, Hackman
et al. (2011) collected four informative new Finnish families
leading the way to the identification of the genetic cause of
LGMD1D. The presence of informative recombination in two
unaffected members of two of these families allowed reducing
the 7q region to 3.4 Mb, containing 12 known genes, and at least
14 hypothetical genes or pseudogenes. Subsequently, a candidate
gene sequencing approach let Sarparanta et al. (2012) to identify
the LGMD1D causative gene.
With the discovery of novel mutations in the DNAJB6 gene,
the spectrum of related phenotypes, in terms of age of onset,
severity and group of muscles involved, is widening.
In the present review we will focus our attention on
the pathological effects of mutations affecting the DNAJB6
chaperone protein, and on the clinical and histopathological
features of the DNAJB6-related myopathies.
MOLECULAR ASPECTS OF DNAJB6
Cells, at each stage of their life, depend on the essential
support of proteins as building blocks and to carry out all
cellular functions. Proteins have a proper three-dimensional
conformation, which, as demonstrated by in vitro experiments
(Anfinsen, 1973), depends on the amino acid sequence and can
be achieved spontaneously according to the global minimum of
free energy. However, the experimental conditions required for
a proper in vitro folding are very restrictive and not applicable
to the crowded cellular environment where hydrophobic effects
will make harder to control the folding. Moreover, this process
is challenged by various stress conditions, some, such as the
increase in protein synthesis during cell cycle progression,
constitutive; others, such as environmental or pathophysiological
stresses (e.g., temperature increase or tissue injury and repair),
sporadic. Therefore, in order to prevent the formation of toxic
protein aggregates, the cell requires an active and dynamic system
able to control proper protein folding and clearance of the
misfolded and damaged proteins.
Molecular chaperones are part of this dynamic system that
helps maintaining cellular protein homeostasis through their
ability to interact among themselves and with specific partners,
thus influencing conformation and function of a wide range of
different substrates such as p53 and other transcription factors,
including steroid receptors, as well as proteins that unfold
and aggregate in neurodegenerative diseases (polylglutamine
androgen receptor, huntingtin, α-synuclein, tau) and a variety of
protein kinases (Morimoto, 2008; Pratt et al., 2015). They are
named heat shock proteins (HSPs) and grouped into families
according to their molecular weight: Hsp100, Hsp90, Hsp70,
Hsp60, Hsp40, and sHsp (small heat-shock protein). The Hsp70
chaperones are involved in a plethora of processes including
folding of newly synthesized proteins, transport of proteins
across membranes, refolding of misfolded and aggregated
proteins, and control of regulatory protein activity (Bukau et al.,
2006). Hsp70 chaperones have a 40 kD N-terminal ATPase
domain and a 25 kDa C-terminal peptide-binding domain
(PBD), and cycle between ATP- and ADP-bound conformation.
In the ATP form, the bond between client polypeptides (newly
synthesized or misfolded proteins) and the PBD of Hsp70, is
weak.
The chaperone-client polypeptide interaction is stabilized by
the intervention of co-chaperone proteins belonging to the DnaJ
family (Hsp40). The DNAJ co-chaperones associate with the
client proteins presenting them to the Hsp70 chaperone, thus
leading to the formation of a trimeric complex. Co-chaperone
plus substrate stimulate the Hsp70 dependent hydrolysis of ATP
to ADP with consequent conformational change of the Hsp70
protein that increases its affinity for the substrate and triggers
the separation of the DnaJ co-chaperone. The release of the
client protein is then achieved by the dissociation of ADP,
stimulated by nucleotide exchange factors (NEFs), allowing the
Hsp70 chaperone to be ready for a new cycle (Laufen et al., 1999;
Kampinga and Craig, 2010; Figure 1).
DNAJ/Hsp40 co-chaperones are a diverse and large group
of proteins characterized by the presence of a 70 amino acid
sequence, the J domain, as common signature. The J domain
stimulates the Hsp70 ATPase activity and contains a conserved
tripeptide sequence (histidine, proline and aspartic acid, HPD)
critical for its function. The Hsp40 family is divided into three
subtypes according to their structure (Figure 2). The type I, or A,
is closely related to the E. coli DnaJ and comprises the J domain
at the N-terminus, a glycine/phenylalanine (G/F)-rich domain, a
cysteine-rich region, and a C-terminal region that recognizes and
binds to the substrate. The direct function of the G/F domain is
not clear. A likely one is that the G/F domain participates in the
recognition and modulation of particular substrates, thus acting
on the specification of Hsp70 function (Fan et al., 2003). The
DNAJ type II or B, has similar structure to type A, but lacks the
cysteine-rich domain. The type III, or C, contains, as conserved
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FIGURE 1 | The Hsp40-Hsp70 cycle. Hsp40 co-chaperone forms complexes with unfolded or non- native proteins delivering them to Hsp70. The interaction
between Hsp40 and the ATP-bound Hsp70 takes place through the J-domain. The client protein transiently interacts with the Hsp70 and the interaction is stabilized
by a conformational change in Hsp70 caused by the hydrolysis of ATP which, in turn, is stimulated by both Hsp40 and client protein. Hsp40 is then released. A
nucleotide exchange factor (NEF) then binds Hsp70 (having more affinity for the ADP-bound form compared to the ATP form), stimulating the dissociation of ADP
through a conformational change in Hsp70. An ATP molecule is bound again to Hsp70 because of its higher cellular concentration, causing the release of the client
protein. The system is then ready for a new cycle (Kampinga and Craig, 2010).
FIGURE 2 | The DNAJ protein family. Based on their structure, DNAJs are divided into three subtypes. Type I, or A, has an N-terminal J domain (with a conserved
histidine, proline, and aspartic acid tripeptide), followed by a glycine/phenylalanine-rich domain (G/F), by a zinc finger region rich in cysteine, and by a C-terminal
domain, responsible for client binding and presenting two barrel domains, CTDI and CDTII. Type II, or B, is similar to type I, but lacks the zinc finger region. Type III, or
C, has only the conserved J domain which is variably located in the protein (Fan et al., 2003).
region, only the J domain, which can be localized anywhere in the
protein (Li et al., 2009; Kampinga and Craig, 2010).
Even though it has been demonstrated that the J domain
alone is capable of stimulating the ATPase activity of Hsp70,
the presence of a functional Hsp70 PBD is required to allow the
formation of a complex between the unfolded protein and Hsp70
(Fan et al., 2003). DNAJ proteins, promote multiple functions of
Hsp70 by binding and delivering a variety of non-native clients.
Some DNAJ chaperones are involved in the correct folding of
the newly synthesized proteins (DNAJA1 and DNAJB1), some
have a role in delivering misfolded proteins to the nucleus for
proteasomal degradation (DNAJB1), some (DNAJB9, DNAJC10,
DNAJB11) intervene in the endoplasmic-reticulum-associated
protein degradation (ERAD) pathway, recognizing misfolded
proteins that are consequently ubiquitinylated and degraded
(Park et al., 2013; Dekker et al., 2015).
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A distinctive characteristic of DNAJB6 and DNAJB8 is their
capability to act as powerful inhibitors of misfolded poly-
Q protein aggregation, which is dependent on and occurs
through direct interaction with the C-terminus SSF-SST serine-
rich region (Hageman et al., 2010; Gillis et al., 2013). The
purified DNAJB6 protein is able to inhibit the formation of
pathogenic polyQ aggregates at a substoichiometric molar ratio
and independently from the presence of Hsp70 and ATP
(Månsson et al., 2014). Unlike in purified protein, in living
systems there is need for interaction between DNAJB6 and
Hsp70 in those situations in which the DNAJB6 anti-aggregation
capability is somehow limited (Kakkar et al., 2016).
This thorough study by Kampinga’s group also demonstrated
that the most efficient anti-aggregation activity is dependent on
an array of 18 hydroxyl groups in the S/T-rich region of DNAJB6.
Additional evidence of DNAJB6 anti-aggregation property comes
from demonstration that overexpression of the human DNAJB6b
in yeast could directly prevent [URE3] prion formation and
block the propagation and spontaneous formation of Ure2
amyloid fibers (Reidy et al., 2016). This further proof indicating
DNAJB6 as anti-aggregant acting on structurally different types
of amyloids, makes DNAJB6 an attractive therapeutic target in
amyloid storage disorders.
In general, because of their involvement in the diverse tasks
of protein homeostasis control, DNAJ proteins are also clinically
relevant disease targets. In fact, mutations leading to disease
have been found in seven distinct DNAJ proteins, comprising
DNAJB2, DNAJB6, DNAJC5, DNAJC6, DNAJC13, DNAJC19,
and DNAJC29 (Koutras and Braun, 2014).
The present review will focus on mutations affecting the
chaperone DNAJB6 (Figure 3), causing limb-girdle muscular
dystrophy type 1D (LGMD1D) and, as shown by recent reports,
other forms of myopathy affecting distal muscles. DNAJB6 is
ubiquitously expressed as two isoforms with distinct cellular
localizations: The longer DNAJB6a localizes to the nucleus and
the shorter DNAJB6b localizes to both the cytoplasm and the
nucleus.
In the thorough work of Udd’s group (Sarparanta et al.,
2012), the molecular mechanisms explaining the dominant
form of LGMD1D affecting Finnish, American, and Italian
patients sharing the common 7q36 locus, were investigated.
These authors showed that, in muscle tissue, DNAJB6 protein
is primarily localized at the Z-disks, and that in LGMD1D
patients a Z-disk myofibrillar disintegration was visible with
accumulation of DNAJB6 and its known ligands MLF1 (myeloid
leukemia factor 1), HSPA8 and KRT18 (keratin 18). With
the use of morpholino (MO) in in vivo experiments on
zebrafish, they were able to demonstrate loss of muscle integrity
caused by the silencing of dnajb6b (the unique ortholog of
the human gene), impairment visible already at 2 days post
fertilization in injected embryos. Expression of the human wild-
type DNAJB6 could rescue the phenotype thus demonstrating
that loss of DNAJB6 was the direct cause of muscle defects.
Furthermore, to investigate the effects of specific mutations on
the a and b isoforms, human mutated transcripts generated for
both isoforms were injected into zebrafish embryos showing
that only the b isoform recapitulates the muscular phenotype
observed with the dnajb6 splice blocking morpholino. Moreover,
Sarparanta and coll. showed that the molar ratio of mutant to
wild-type DNAJB6 mRNA is crucial: An equimolar injection
of mutant and wild type DNAJB6 messenger will increase the
severity of the phenotype, suggesting a dominant effect. An
excess of mutant over wild-type is lethal for embryos, while the
opposite allows a progressively increasing rescue. Using a filter
trap assay, the mutant proteins were shown to have reduced anti-
aggregation properties of polyglutamine-containing huntingtin
(pEGFP/HD-120Q), compared to wild-type DNAJB6 protein,
confirming data previously found by Hageman et al. (2010). The
reported mutations, although not affecting the S/T-rich region
proven to be responsible for the anti-aggregation activity (Kakkar
et al., 2016), might indirectly alter this property—e.g., modifying
the protein conformation and impairing the interaction with
different clients—thus causing protein accumulation in patient’s
muscles and variability of clinical severity.
Because of the Z-disk localization and the interaction of
DNAJB6 with HSPA8, one of the components of the chaperone-
assisted selective autophagy (CASA) complex (Izawa et al., 2000;
Arndt et al., 2010), the authors investigated the possible link
between DNAJB6 and CASA. By co-immunoprecipitation and
proximity ligation assay, the authors showed interaction of
DNAJB6 with the components of the CASA complex BAG3
(a protein found to be mutated in myofibrillar myopathy type
6), HSPB8 and STUB1, but none of the interactions appeared to
be affected by the p.Phe93Leu DNAJB6 mutation. The authors
concluded that the myofibrillary muscle tissue phenotype of
LGMD1D patients could be due to an inefficient maintenance
of the sarcomeric structure or an increased accumulation of
misfolded sarcomeric proteins caused by the impairment of the
CASA system, although experimental evidence of a direct role of
DNAJB6 in the CASA machinery has yet to be provided.
Another important work investigating the effects of the
LGMD1D mutations, by Stein et al. (2014), exploited the yeast
ortholog Hsp40 Sis1, creating a Sis1-DNAJB6 protein chimera
in which the G/F domain of DNAJB6 was substituted to that
of Sis1. With the use of the prion strains of [RNQ+] and
[PSI+], Stein and coworkers, showed that, compared to the wild
type chimera, in the LGMD1D mutant chimera the ability to
process the protein aggregate conformers was impaired. They
also investigated these findings in a mammalian system by
monitoring TDP-43 aggregate formation in HeLa cells upon
heat-shock and during recovery. TDP-43 contains a C-terminal
prion-like domain (Fuentealba et al., 2010) and forms aggregates
in skeletal muscle of DNAJB6-mutated patients (Harms et al.,
2012). In Hela cells expressing TDP-43 and DNAJB6 mutations
and in primary patients’ fibroblasts, TDP-43 aggregates persisted
after heat-shock and recovery, but not in Hela cells expressing
DNAJB6-wild type and in control fibroblasts, thus confirming
previous suggestion that TDP-43 is a client protein of DNAJB6
(Udan-Johns et al., 2014). These authors proposed that a different
degree of selectivity for substrate conformers would be conferred
to the co-chaperone protein by the G/F domain: Different
mutations in this domain would disrupt the substrate selectivity
differentially, thus providing an explanation for the diverse
clinical presentations of DNAJB6-related myopathies.
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FIGURE 3 | The DNAJB6 protein. The J, G/F and C-terminal domains, and position of the amino acid and splicing mutations are represented (Fan et al., 2003; Sato
et al., 2013; Ruggieri et al., 2015).
ANIMAL MODELS
In addition to the zebrafish utilized by the Udd’s group
(Sarparanta et al., 2012) to demonstrate that DNAJB6 was the
gene responsible for LGMD1D, very recently the Drosophila
melanogaster has been used to establish a mechanistic link
between the human genes DNAJB6 and hnRNPA2B1 (causing
multi system proteinopathy and autosomal dominant familial
amyotrophic lateral sclerosis) (Li et al., 2016). These authors
generated transgenic Drosophila lines either carrying mutations
in Hrb98DE (the fly homolog of hnRNPA2B1) or in MRJ (the
fly homolog of human DNAJB6), in amino acids corresponding
to those mutated in LGDM1D patients. They demonstrated
that the cytoplasmic aggregation and mislocalization of the
mutant Hrb98DE and hnRNPA2B1 proteins, was rescued by
co-expressing the wild-type MRJ but not the disease-associated
MRJ mutant. In addition, partial reduction of the endogenous
MRJ levels, obtained using a classical loss of function line,
caused great increase in cytoplasmic aggregation of the mutant
Hrb98DE. Finally, the authors showed that an intact G/F domain
is indispensable for controlling the formation of mutation-
dependent Hrb98DE or hnRNPA2 cytoplasmic aggregates.
The first study of DNAJB6 homolog gene in mouse was
published in 1999 (Hunter et al., 1999). These authors identified,
by gene trap screen, the Mrj (mammalian relative of DnaJ) gene
and characterized its expression during mouse development,
showing thatMrj is expressed throughout the trophoblast lineage
with higher levels in the trophoblast giant cells of the placenta.
The homozygous Mrj mutants were lethal because of a failure
in chorioallantoic fusion at embryonic day 8.5. Eight years later
Watson et al. (2007) demonstrated that absence of a functional
Mrj protein in trophoblast cells, causes the deposition of keratin
aggregates that disrupt cell function and organization, leading to
defects in chorioallantoic fusion.
A mouse model for the study of DNAJB6-related myopathy
has recently been established by Bengoechea et al. (2015). These
authors generated, under the muscle creatine kinase (MCK)
promoter, four different transgenic animals, for both the long
and short DNAJB6a and DNAJB6b isoforms: Two wild-type
and two with the most common human mutation F93L. The
authors observed that the DNAJB6b-F93L protein levels were
higher than those of the wild type protein, and showed that
this was due to a slower degradation rate of the mutant protein
compared to the wild-type. Bengoechea and coworkers also
demonstrated that only the DNAJB6b-F93L mutant construct
was able to induce some of the pathological features of the
LGMD1D phenotype, such as muscle weakness, myofibrillar
disorganization, desmin accumulation, autophagic vacuoles,
and aggregation of RNA binding proteins (hnRNAPA1
and hnRNAPA2/B1). Electron microscopy highlighted
myofibrillar disorganization, mitochondrial alteration and
presence of autophagic vacuoles. Immunostaning showed
desmin, keratin 8 and 18 accumulation in muscle fibers,
and aggregation of RNA binding proteins (hnRNAPA1 and
hnRNAPA2/B1).
Another recent interesting mouse model, by Kakkar et al.
(2016) overexpressing the human DNAJB6 protein under control
of a brain-specific nestin promoter, although not directly related
to muscle diseases, shows the potential of DNAJB6 as therapeutic
target in protein aggregate disorders. This mouse was crossed
with the R6/2 polyQ mice (HTT), model for Huntington disease.
The double transgenic mice HTT/DNAJB6 had a significant
reduction of inclusions in the brain only and a better rotarod
test performance, when compared to the HTT mice. Since
the overexpression of DNAJB6 protein in brain did not show
secondary effects in these animals, the authors speculate that
DNAJB6 could be a valid therapeutic target in polyQ disorders.
CLINICAL FEATURES OF
DNAJB6-RELATED MYOPATHIES
Clinical features are summarized in Table 1 and
histopathological aspects are represented in Figure 4.
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FIGURE 4 | Histopathological features of muscle biopsies from
DNAJB6-mutated patients. H&E (A,B) and Gomori trichrome stains (C,D)
reveal several autophagic vacuoles, visible either in subsarcolemmal regions or
centrally located, internalized myonuclei as well as variability in fiber sizes
(Ruggieri et al., 2015).
In the first description of the “unusual form of muscular
dystrophy” in the paper by Schneiderman et al. (1969), clinical
symptoms presented since the third decade of life, manifesting as
difficulty in climbing stairs, subsequently followed by proximal
upper limb muscles weakness. No bulbar or facial muscle
involvement were reported. Disease progression was slow over
the years, with only two patients in their seventies being
bedridden. Electromyography was normal, as normal were
mental abilities. Light microscopy of deltoid muscle biopsies of
clinically affected subjects, showed marked variation in fiber size,
numerous vacuolated fibers, and slight increase in connective
tissue and fat. At the electron microscopy some of the myofibers
presented foci of degenerated myofibrils at the center and in
the subsarcolemmal regions, which were replaced by granular
or vacuoles containing myelin-like bodies, dense lysosomal-like
structure, and dilated vesicles.
Subsequent linkage studies on Schneiderman’s patients and
additional American and Finnish families by several groups
(Speer et al., 1995, 1999; Sandell et al., 2010; Hackman et al.,
2011) allowed the identification of a common haplotype on
7q36, a region of 3.4 Mb, containing 12 known genes. All the
patients were characterized by late onset progressive proximal
lower limb muscle weakness with or without proximal upper
limb involvement, increased CK levels, absent ankle deep
tendon reflexes, and no features suggestive of any other known
myopathy. Histology of different lower limb muscles (vastus
lateralis, medial gastrocnemius, or soleus) displayed myopathic
and dystrophic features, rimmed vacuoles and protein aggregates.
Sequencing of the candidate genes among the 12 present in
the linked region, allowed Sarparanta et al. (2012) to identify the
genetic cause of LGMD1D in the DNAJB6 gene. The changes
were all point mutations, notably c.279C>G (p.Phe93Leu)
in the Finnish families, c.267T>A (p.Phe89Ile) in the
American families, and c.279C>A and c.277T>C (p.Phe93Leu)
in further Italian families. Interestingly, all the reported
mutations were in the exon 5 of the gene, encoding the G/F
domain.
The association of these clinical features with mutations in the
DNAJB6 gene and the use of new sequencing technologies
allowed the identification of novel mutations in more
LGMD1D patients. By exome sequencing in patients that
presented with dominant or sporadic myopathy and that
were genetically unresolved, Harms et al. (2012) identified
DNAJB6 mutations in two new families, in particular a
c.277T>C (p.Phe93Leu) and a c.287C>G (p.Pro96Arg)
change. Of the two mutated families though, one Caucasian
presented weakness in the limb-girdle muscles, while the
second, of African American origin, had predominant
lower limb distal weakness, which had never been reported
before. The number of published mutations and ethnicity
increased with the description of four additional Japanese
families by Sato et al. (2013) and two further cases with
childhood onset and lower limb proximal muscle weakness
described by Suarez-Cedeno et al. (2014) and Couthouis et al.
(2014).
Of note, one Japanese patient carrying the Phe93Leumutation
was detailed (Yabe et al., 2014) as having developed fronto-
temporal dementia (FTD). His cognitive impairment worsened
with age and the patient died at 76 years of age. The
immunoreactivity of DNAJB6 in the frontal cortex was greatly
reduced as compared with other forms of dementia, but was
normal in the thalamus. In the fronto-temporal cortex ubiquitin-
positive aggregates were also present. No mutations in any of the
known FTD genes were revealed. Based on altered LC3 and p62
immunostaining of the frontal lobe of this patient, the authors
suggested a possible impairment of the autophagy pathway such
as seen in patients with VCP gene mutations. Considering that
this suggestion is solely based on histological findings, further
investigation to prove its accuracy will be necessary, as stated by
the authors themselves.
More recently, the widening of the phenotypic spectrum
of DNAJB6-related myopathies was confirmed and a tentative
genotype-phenotype correlation was hypothesized. In the work
by Ruggieri et al. (2015), the authors redefined the genetic
locus and some clinical features of a previously reported family
with “autosomal dominant vacuolar neuromyopathy” (Servidei
et al., 1999). By whole exome sequencing, a novel missense
mutation in the DNAJB6 gene, a c.298T>G (p.Phe100Val),
was identified in this family. Again, this mutation affects a
conserved amino acid of the G/F domain. Moreover, four
sporadic cases were reported, one with a known transition
c.279C>G (p.Phe93Leu) and three with novel mutations of
the G/F domain: Two missense, c.271T>A (p.Phe91Ile), and
c.273C>G (p.Phe91Leu), and one, c.346+5 G>A, leading to
an alternative splicing event causing the skipping of exon 5.
Clinically the two patients carrying the different mutations
of Phe91 had a severe childhood-onset limb-girdle myopathy.
The patients with the Phe100Val mutation had distal-onset
myopathy, unique early bulbar involvement, and a gender-
modified wide age-of-onset range. The patient with the splicing
defect that entirely eliminates DNAJB6’s G/F domain (1G/F),
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had severe distal childhood-onset myopathy. Muscle imaging
revealed that muscles previously considered uninvolved in
DNAJB6-myopathy, e.g., lateral gastrocnemii, were affected in
patients with new mutations. The authors observed that the
mutations affecting the amino acid in the more C-terminal
part of the G/F domain (Pro96 and Phe100 in this) as well
as the mutation causing skipping of the entire G/F domain
were correlating with a more distal phenotype compared to
the more N-terminal amino acids (Phe89, Phe91, and Phe93).
Furthermore, they highlighted the fact that there seems to
be a range of severity correlating with the different DNAJB6
mutations so far reported, even though more cases are necessary
to confirm this hypothesis. In particular, from most severe to
least severe LGMD1D phenotype, the mutations are as follow:
1G/F and Phe91 mutations, Phe100Val, Pro96Arg, and Phe89
mutations and Phe93 mutations.
This genotype-phenotype correlation was once more
confirmed by Palmio et al. (2015), reporting a Finnish
family and a sporadic British female case with a severe
form of LGMD1D with childhood onset, rapidly progressing
to loss of walking ability within the end of the third
decade, contractures and respiratory failure. The patients
carried mutations of the Phe91 amino acid, respectively
c.271T>A (p.Phe91Ile) and c.271T>C (p.Phe91Leu).
Likewise, the severe phenotype associated to the Phe91Leu
was observed by Nam et al. (2015) in a Korean LGMD1D
family with childhood onset and fast progression of the
symptoms as well as involvement of respiratory and bulbar
muscles.
It is intriguing to note that the correlation between genotype
and clinical presentation can be seen as well with the use of
imaging techniques. In fact, muscle imaging has shown that
the pattern of muscle involvement appears to be more variable
than previously thought and somewhat different according to
the mutated amino acid. Indeed, in 2013 Sandell et al. (2013),
published the first analysis of muscle MRI or CT features
in 23 Finnish and Italian DNAJB6 mutated patients. All the
patients carried mutations affecting the Phe93 amino acid. The
pattern and timing of engagement of the imaged muscles were
consistent among all the patients and considered pathognomonic
for LGMD1D: At the early stages of the disease the more affected
muscles were soleus, adductor magnus, semimembranosus, and
biceps femoris, then the medial gastrocnemius and adductor
longus, and finally also the vasti muscles of the quadriceps
resulted to be compromised. The muscles that were affected only
in a very late stage of the disorder were lateral gastrocnemius,
rectus femoris, sartorius, gracilis, and the anterolateral muscles
of the lower legs. However, it was later on shown that this
pattern of involvement was slightly different in patients with
the Phe91, Phe100, and 1G/F changes (Nam et al., 2015;
Palmio et al., 2015; Ruggieri et al., 2015). In patients with
these mutations, the recti, sartorii, gracilis, and anterolateral
muscles were relatively spared, but the lateral gastrocnemii were
greatly compromised already in relatively early stages of the
disease.
CONCLUSIONS
With the discovery of novel mutations in the DNAJB6 gene,
the spectrum of related phenotypes, in terms of age of onset,
severity and group of muscles involved, is expanding. The
number and type of mutations (all but one missense) so
far appears limited, involving a few amino acids of the G/F
domain.
Although our knowledge of the role of DNAJB6 in the
pathogenesis of muscle diseases has made great progression,
several questions remain unsolved:
(1) DNAJB6 is a ubiquitous protein. Therefore, why do DNAJB6
mutations affect mainly skeletal muscle and rarely the
central nervous system (as known so far), and why has
no cardiac involvement been reported in these patients?
Possible explanations include the selective expression of a
DNAJB6 client protein in skeletal muscle, the interaction
of DNAJB6 with the CASA system particularly with BAG3
(already known to cause a myofibrillar myopathy), or a
functional redundancy of DNAJ family members in all
tissues except skeletal muscle.
(2) Why are only mutations of the G/F domain implicated? Are
any other regions of the protein more flexible and therefore
more adaptable to variations, or are mutations in other
regions lethal? In this context, the animal models could be
useful in preclinical studies addressed to better understand
the physio-pathological mechanisms involved in DNAJB6-
related myopathies.
(3) Is there a function for the DNAJB6a isoform in muscle?
It is known that it reduces malignancy in several forms
of cancer by acting on AKT and β catenin pathways (Yu
et al., 2015). Could this be related to a possible role of
DNAJB6a in fine-tuning of critical cellular signaling also in
muscle?
The clarification of these issues and of the molecular
mechanisms driven by DNAJB6 protein will provide the
knowledge for implementing therapeutic strategies for patients
with DNAJB6-related myopathies, as well as for patients
with neurodegenerative diseases caused by toxic protein
aggregation.
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